You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Dual Fatty Acid Amide Hydrolase (FAAH)/Monoacylglycerol lipase (MAGL) Inhibitors for Cannabis Use Disorder (CUD).
SBC: MAKSCIENTIFIC Topic: NIDAOTHER PROJECT INFORMATION – Unit 7 – Project Summary/Abstract This project addresses the growing need for medications for cannabis use disorder (CUD) which, in the absence of approved medications, is a major focus of NIDA’s mission. Currently available cannabinergic-based treatments for CUD include the directly acting CB1 agonists, e.g., Δ9-THC or nabilone, which have been reported to reduc ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Field Instrument for Assessment of Arsenic Exposure
SBC: GINER INC Topic: RProject Summary Human exposure to toxic heavy metals existing in drinking water, food, and the environment is an area of increasing national and international concern. Heavy metals are significant environmental pollutants because they tend to persist, bioaccumulate and can result in serious adverse acute or chronic health effects after ingested or inhaled. Traditionally, trace metals are measured ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Evaluation of a Novel Immunomodulatory Vaccine for Preventing and Treating HSV Infections
SBC: Rational Vaccines, Inc. Topic: NIAIDPROJECT SUMMARY: Herpes Simplex Virus (HSV) infections are common, infecting more than half of the world’s population. While most cases of genital herpes are caused by HSV type 2 (HSV-2), it is estimated that more than 150 million people aged 15-49 have genital HSV type 1 (HSV-1) infections. Although several vaccines have been evaluated for preventing/treating HSV infections, none have received ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical validation of small molecule immunomodulators for the treatment of Crohn's disease
SBC: PROMAKHOS THERAPEUTICS INC Topic: 300Project Summary Crohn’s disease is a debilitating and chronic inflammatory disorder of the gastrointestinal tract characterized by aberrant healing and intestinal stricturing. In the US, rt500,000 patients suffer from Crohn’s disease and over 30,000 patients are newly diagnosed each year. No curative treatments exist. Instead, current treatments focus on managing symptoms and reducing the occu ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Improved optimization of covalent ligands using a novel implementation of quantum mechanics suitable for large ligand/protein systems.
SBC: QUANTUM SIMULATION TECHNOLOGIES INC Topic: 400Project Summary The value of computational chemistry to commercial drug discovery is now well-established. Virtual screening (including molecular docking) now jumpstarts most discovery efforts. Tools such as molecular dynamics and free energy perturbation are increasingly used to inform the later stages of lead refinement. The growing importance of computational structure-based methods has influen ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Consumer-Therapist-Connector: Increasing Access to Quality Behavioral Healthcare
SBC: OUTCOME REFERRALS INC Topic: 104ABSTRACT The United States is experiencing a major mental health crisis. Per recent reports in the New York Times and The Washington Post, the gap between need and access to behavioral health services is rapidly increasing. There is an urgent need to solve both the access and quality problems with behavioral healthcare. With COVID and other stressors, 76% of surveyed employees are reporting at lea ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
New generation of catheters for treatment of atrial fibrillation
SBC: LUXMED SYSTEMS INC Topic: NHLBIABSTRACT Atrial fibrillation (AF) remains the most commonly occurring cardiac arrhythmia. It is associated with a lower quality of life and a higher rate of morbidity and mortality primarily due to poor hemodynamic performance and often stroke. One of the primary options to treat AF is cardiac ablation where the physician applies radiofrequency energy via percutaneous catheters to form a series of ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
First-in-class TREM-1 inhibitors for neovascular retinal diseases
SBC: SIGNABLOK, INC. Topic: 100Project Summary/Abstract Retinal neovascularization (RNV) is a major cause of vision loss in retinopathy of prematurity (ROP), diabetic retinopathy (DR) and retinal vein occlusion. In the US, about 16,000 of premature infants are affected by ROP annually and about 4.1 million adults years have DR. Complications of conventional treatments suggest an unmet need for new therapies. The long-term objec ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Topical Eyedrops Increasing Lysyl Oxidase Activity to Control Myopia
SBC: Iveena Delivery Systems, Inc. Topic: NEIProject Summary Pediatric myopia, also known as nearsightedness, is an eye condition in which one is unable to bring distant objects into proper focus. It is the leading cause of vision impairment in the world. The estimated economic impact of uncorrected refractive error is estimated to be a loss of $202 billion of global gross domestic product. The prevalence of myopia and high myopia are increa ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
In vivo Evaluation of USP30 Inhibitors in Models Relevant to Parkinson's Disease
SBC: VINCERE BIOSCIENCES INC Topic: 999ABSTRACT Existing treatments for Parkinson’s disease (PD), which affects 10 million people worldwide, primarily augment dopaminergic neurotransmission to provide symptomatic benefit. No current therapy can slow or stop the progression of PD. We propose a drug discovery platform to develop small molecules targeting the parkin-USP30 mitophagy pathway, which represents a key regulator of mitochondr ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health